Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $125.00 Price Target at Stifel Nicolaus

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target upped by Stifel Nicolaus from $98.00 to $125.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also recently weighed in on the stock. HC Wainwright increased their price target on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Citizens Jmp lowered their price objective on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating for the company in a research note on Thursday. Wall Street Zen raised Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $114.92.

Mirum Pharmaceuticals Price Performance

MIRM opened at $92.19 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The stock’s 50 day simple moving average is $93.11 and its 200 day simple moving average is $78.90. The firm has a market cap of $4.74 billion, a price-to-earnings ratio of -192.06 and a beta of 0.49. Mirum Pharmaceuticals has a 1 year low of $36.88 and a 1 year high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.98%. The company had revenue of $148.93 million for the quarter, compared to analysts’ expectations of $141.78 million. During the same period last year, the company posted $1.00 EPS. The business’s revenue for the quarter was up 49.8% compared to the same quarter last year. As a group, analysts predict that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Christopher Peetz sold 9,108 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $940,856.40. Following the sale, the chief executive officer directly owned 160,294 shares in the company, valued at $16,558,370.20. The trade was a 5.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Eric Bjerkholt sold 1,421 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total value of $132,621.93. Following the completion of the transaction, the chief financial officer owned 42,127 shares of the company’s stock, valued at approximately $3,931,712.91. This trade represents a 3.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 45,136 shares of company stock worth $4,352,029 over the last quarter. Company insiders own 14.36% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cullen Frost Bankers Inc. purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $30,000. MCF Advisors LLC increased its position in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in Mirum Pharmaceuticals during the fourth quarter valued at $32,000. CIBC Private Wealth Group LLC bought a new stake in Mirum Pharmaceuticals in the fourth quarter worth $32,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals in the third quarter worth $33,000.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Revenue beat and strong product growth—Mirum posted ~50% y/y revenue growth driven by Livmarli and other bile-acid therapies, beating Street revenue estimates, which supports the company’s top-line trajectory. Article Title
• Positive Sentiment: Corporate release and call provide detail and FY revenue guide—Mirum’s press release and earnings call outlined operations and gave FY2026 revenue guidance ($630M–$650M), offering a revenue roadmap for investors even as EPS guidance/detail was limited. Article Title
• Positive Sentiment: Analysts largely remain bullish — multiple firms raised or reiterated positive ratings and targets (TD Cowen, Stifel Nicolaus, RBC and others continue to show upside vs. the current price), signaling analyst confidence in longer-term upside despite short-term noise. Article Title
• Neutral Sentiment: Transcripts and analysis available—Earnings-call transcripts and analyst writeups (Seeking Alpha, The Motley Fool, Zacks) give more color for investors deciding whether the EPS miss is a one-off or structural. Use these to dig into margins, SG&A, and commercial execution details. Article Title Article Title
• Negative Sentiment: EPS miss and margin concerns—Mirum reported ($0.11) EPS vs. a ~$0.02 consensus, a significant miss that triggered the selloff despite the revenue beat; investors are focused on margins, profitability timeline, and whether EPS guidance will be conservative. Article Title
• Negative Sentiment: Immediate market reaction and volume—Coverage and commentary (AAII and others) point to the EPS miss + any perceived conservative guidance as the proximate cause of today’s decline; heavy volume suggests short-term technical selling even as analysts debate the longer-term story. Article Title

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.